Drug
Enzalutamide capsule
Enzalutamide capsule is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
2(50%)
Results Posted
100%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Terminated(1)
Detailed Status
Terminated1
Completed1
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
terminated125%
completed125%
recruiting125%
active_not_recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruitingphase_2
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
NCT04655365
recruitingphase_2
Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
NCT06582628
terminatedphase_1
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
NCT03478904
completedphase_1
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
NCT01902251
Clinical Trials (4)
Showing 4 of 4 trials
NCT04655365Phase 2
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
NCT06582628Phase 2
Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
NCT03478904Phase 1
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
NCT01902251Phase 1
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4